Centre for Haemato-Oncology

This Centre seeks to understand the molecular basis for lymphoma, leukaemia and myeloma to identify targets for novel targeted therapies and to identify biomarkers of prognosis and response to treatment. We also seek to understand the impact of the tumour microenvironment on malignant cell survival and resistance to therapy. A long-standing strength has been the translational components with strong links to the clinic through clinical senior lecturers and clinical research fellowships and high enrolment of patients in clinical trials.  Our main research interests are:

  • Cancer Immunotherapy:
    The aim is to develop immunotherapy approaches for the treatment of cancer, including stem cell transplantation; and to identify tumour antigens.
  • Applied Haemato-Oncology Group:
    The aim is to characterise the molecular signature of lymphomas to identify recurrent genomic and expression changes within these lymphomas to guide treatment selection.
  • Cancer Genomics:
    The aim is to understand the key genetic events in malignant transformation through molecular cytogenetics, SNP genotyping approaches and high throughput genomic sequencing.
  • Clinical Cancer Pharmacology:
    We conduct pharmacodynamic and pharmacokinetic studies of cytotoxic agents to develop and test new agents in the laboratory and in clinical trials. The goal is to optimise the use of chemotherapy drugs through a better understanding of their molecular and clinical pharmacology.
  • Leukaemia Biology:
    Our research focuses on elucidating the biology of leukaemia initiating cells (LIC’s). By improving our understanding of the cellular basis of leukaemia initiation and maintenance we aim to shed light on how malignant growth is sustained in leukaemia and how this related to tumour recurrence following therapeutic intervention. These insights will ultimately inform the development of effective therapeutic approaches that can improve patient survival rates.

Group Leaders in the Centre


Life In The Centre

Get a sense of what life is like for researchers in our centre:

Results & Discoveries


  • Discovered new functions of 5-hydroxymethylcytosine and pioneered the field of this novel epigenetic modification. PMID: 21460836
  • Identified major reprogramming events in embryonic stem cells in the ground state pluripotency. PMID: 23850245

Cell Signalling

  • The tumour microenvironment modulates the ability of PI3K inhibitors to induce apoptosis in cancer cells. PMID: 24648465
  • Environmental stress modulates the activity of cancer signalling networks. PMID: 24425749
  • A novel MS-based assay predicts responses of tumour cells to new cancer drugs. PMID: 23628362
  • A new computational method to analyse MS data identifies the most frequently over-activated kinases in primary leukaemia cells and predicts reponses to a PI3K inhibitor. PMID: 23330613

Precision Medicine

  • Landscape profile of Follicular Lymphoma genome. PMID: 24362818
  • Common progenitor population model of Follicular Lymphoma evolution. Blood, JCO
  • Inherited CEBPA mutations in Acute Myeloid Leukaemia. NEJM


This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.